Fig. 3

a Mean change from baseline FPG (LOCF); b 7-point SMPG profiles from baseline and after 20 weeks of treatment (EOT); c total daily insulin dose. Data from FAS. EOT end of trial, FPG fasting plasma glucose, LOCF last observation carried forward, SMPG self-measured plasma glucose